GOVX

GeoVax is a pre-revenue clinical-stage biotech whose survival, not its pipeline, is the story. The 10-K carries an explicit going-concern opinion and states cash was 'sufficient to fund our operations into mid-second quarter of 2026' — a runway that, as of today, has already elapsed. Against a FY2025 net loss of -$21.5M and operating cash burn of -$21.5M, the company held just $3.09M of cash (down 44% YoY). That is roughly seven weeks of burn. Continued operation is therefore wholly dependent on raising capital 'at various intervals... on terms acceptable to us or at all,' which the filing concedes is not assured.

The income statement offers no offset. What the data labels 'revenue' ($2.49M, down 37.1% YoY) is government-grant and collaboration income — the filing is explicit that there has been 'no product revenue to date.' So the headline P/S of 1.4x is meaningless: you are not buying a 1.4x-sales business, you are buying grant flow against a -869% operating margin and a -561% ROE. Revenue has been erratic and non-recurring ($0 in FY2023, $3.95M in FY2024, $2.49M in FY2025), and R&D of $18.1M dwarfs it. Cumulative retained deficit stands at -$151M.